Desktop Metal, Inc.

    Desktop Metal, Inc.

    NNYSE:DM
    4.96
    USD
    0.00
    (0.00%)
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    TTM
    Revenue per Share
    1.18
    1.04
    4.31
    6.64
    5.89
    5.12
    Basic EPS, GAAP
    -4.61
    -2.15
    -9.22
    -23.52
    -10.03
    -11.11
    Free Cash Flow per Basic Share
    -4.63
    -5.19
    -7.05
    -6.13
    -3.65
    -2.35
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -13.1
    -20.79
    -21.8
    -41.58
    -50.66
    -55.42
    Tangible Book Value per Share
    6.83
    31.93
    13.31
    6.19
    2.28
    -0.09
    Basic Weighted Avg Shares
    22
    16
    26
    31
    32
    33
    Sales/Revenue/Turnover
    26
    16
    112
    209
    190
    168
    Operating Margin (%)
    -412.44
    -558.93
    -156.46
    -111.45
    -106.38
    -142.15
    Depreciation Expense
    8
    9
    25
    51
    54
    117
    Net Income, GAAP
    -104
    -34
    -240
    -740
    -323
    -366
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    -391.83
    -206.53
    -213.81
    -354.19
    -170.41
    -217.2
    Working Capital
    145
    582
    298
    253
    146
    82
    LT Debt
    13
    2
    14
    130
    136
    132
    Total Equity
    159
    516
    1,248
    528
    242
    72
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'24
    ST Debt
    8
    8
    8
    LT Borrowings
    113
    113
    113
    LT Finance Leases
    23
    21
    19
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    33
    33
    33
    Market Capitalization
    285
    135
    154

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'24
    Total Current Assets
    197
    170
    143
    Cash, Cash Equivalents & STI
    66
    46
    31
    Accounts Receivable, Net
    35
    30
    23
    Inventories
    83
    84
    81
    Total Current Liabilities
    70
    65
    61
    Payables & Accruals
    28
    29
    26
    ST Debt
    8
    8
    8
    Deferred Revenue
    18
    14
    16

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    - -
    -54.19%
    Free Cash Flow
    - -
    - -
    -39%
    Net Income, GAAP
    - -
    - -
    -56.33%
    Sales/Revenue/Turnover
    - -
    - -
    -9.25%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    44
    58
    47
    61
    209
    2023
    41
    53
    43
    52
    190
    2024
    41
    39
    36
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -2.24
    -9.48
    -1.92
    - -
    -23.52
    2023
    -1.65
    -1.55
    -1.43
    - -
    -10.03
    2024
    -1.59
    -3.13
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • gurufocus.com

      Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)

    • accessnewswire.com

      Datametrex Announces Director Resignation and Appointment of Director

    • accessnewswire.com

      Datametrex Plans to Focus on AI, Data Centre, and Patent Licensing

    • accessnewswire.com

      Datametrex Announces Name Change and Management Changes

    • accessnewswire.com

      Datametrex Announces Annual and Special Meeting Voting Results

    • accessnewswire.com

      Datametrex Announces Transition to Semi-Annual Financial Reporting

    • accessnewswire.com

      Datametrex Announces Completion of AI-Based Evaluation of 2 Patents and Launch of Licensing Initiative

    • accessnewswire.com

      Datametrex Announces Rebranding of Paymetrex to QuantIP Licensing Corp.

    • gurufocus.com

      FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung

    • accessnewswire.com

      Imagine Health Achieves Teaching Facility Status Through University of Calgary Faculty Partnership

    • accessnewswire.com

      Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate

    • accessnewswire.com

      Datametrex Subsidiary PayMetrex Highlights Strategic Relevance of Patent Portfolio to Rapidly Expanding SoftPOS Market

    • accessnewswire.com

      Datametrex Integrates AI to Healthcare To Enhance Efficiencies

    • accessnewswire.com

      Paymetrex Engages Pelent AI to Accelerate Patent Licensing Program

    • accessnewswire.com

      Datametrex Receives $1M Order from Fortune 500 Client

    • accessnewswire.com

      Datametrex Received $500,000 Purchase Order For Data Centre Solutions

    • accessnewswire.com

      Paymetrex Secures First U.S. License Payment

    • accessnewswire.com

      Datametrex Expands Business In Data Centres

    • accessnewswire.com

      Paymetrex Launches Patent Licensing Program to Monetize Mobile Payments IP Portfolio

    • accessnewswire.com

      Datametrex Announces Participation in AlphaNorth Capital Event